FDA approved a premarket approval supplement application for Novocure’s second generation Optune system. The Tumor Treating Fields delivery system is now available to glioblastoma patients in the U.S. The new model features a generator that is less than half the weight and half the size of the generator in the first generation system. Additional improvements...
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
